Vertex Pharmaceuticals Incorporated Stock Current Liabilities
VX1 Stock | EUR 441.05 0.35 0.08% |
Vertex Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex |
Vertex Pharmaceuticals Incorporated Company Current Liabilities Analysis
Vertex Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
In accordance with the recently published financial statements, Vertex Pharmaceuticals Incorporated has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
All Next | Launch Module |
Vertex Fundamentals
Return On Equity | 0.28 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.37 % | |||
Operating Margin | 0.49 % | |||
Current Valuation | 67.44 B | |||
Shares Outstanding | 257.09 M | |||
Shares Owned By Insiders | 0.21 % | |||
Shares Owned By Institutions | 96.26 % | |||
Price To Earning | 18.50 X | |||
Price To Book | 6.23 X | |||
Price To Sales | 8.51 X | |||
Revenue | 8.93 B | |||
Gross Profit | 5.32 B | |||
EBITDA | 4.44 B | |||
Net Income | 3.32 B | |||
Cash And Equivalents | 3.95 B | |||
Cash Per Share | 15.37 X | |||
Total Debt | 656.95 M | |||
Debt To Equity | 12.90 % | |||
Current Ratio | 3.74 X | |||
Book Value Per Share | 54.13 X | |||
Cash Flow From Operations | 4.13 B | |||
Earnings Per Share | 11.89 X | |||
Price To Earnings To Growth | 0.42 X | |||
Target Price | 258.59 | |||
Number Of Employees | 4.8 K | |||
Beta | 0.46 | |||
Market Capitalization | 70.82 B | |||
Total Asset | 18.15 B | |||
Z Score | 64.2 | |||
Net Asset | 18.15 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.